The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 May 3

PMID 33937042

Citations 11

Authors

Juan Sun

Xianze Wang

Zimu Zhang

Ziyang Zeng

Siwen Ouyang

Weiming Kang

Affiliations

Soon will be listed here.

Abstract

The overall efficacy of neoadjuvant chemoradiotherapy (NACT) for locally advanced gastric cancer (LAGC) has been recognized. However, the response rate of NACT is limited due to tumor heterogeneity. For patients who are resistant to NACT, not only the operation timing will be postponed, patients will also suffer from the side effects of it. Thus, it is important to develop a comprehensive strategy and screen out patients who may be sensitive to NACT. This article summarizes the related research progress on the sensitivity prediction of NACT for GC in the following aspects: microRNAs, metabolic enzymes, exosomes, other biomarkers; inflammatory indicators, and imageological assessments. The results showed that there were many studies on biomarkers, but no unified conclusion has been drawn. The inflammatory indicators are related to the survival and prognosis of patients under NACT. For imageological assessments such as CT, MRI, and PET, with careful integration and optimization, they will have unique advantages in early screening for patients who are sensitive to NACT.

Citing Articles

Deep learning nomogram for predicting neoadjuvant chemotherapy response in locally advanced gastric cancer patients.

Zhang J, Zhang Q, Zhao B, Shi G Abdom Radiol (NY). 2024; 49(11):3780-3796.

PMID: 38796795 PMC: 11519172. DOI: 10.1007/s00261-024-04331-7.

Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification : Immunoneoadjuvant therapy of gastric cancer.

Yao G, Yuan J, Duan Q, Tan Y, Zhang Q, Chen D Invest New Drugs. 2023; 42(1):1-13.

PMID: 37971628 DOI: 10.1007/s10637-023-01406-y.

Predictive value of DNA methylation in the efficacy of chemotherapy for gastric cancer.

Li Y, Mo N, Yang D, Lin Q, Huang W, Wang R Front Oncol. 2023; 13:1238310.

PMID: 37771430 PMC: 10523571. DOI: 10.3389/fonc.2023.1238310.

Digital histopathological images of biopsy predict response to neoadjuvant chemotherapy for locally advanced gastric cancer.

Zhou Z, Ren Y, Zhang Z, Guan T, Wang Z, Chen W Gastric Cancer. 2023; 26(5):734-742.

PMID: 37322381 DOI: 10.1007/s10120-023-01407-z.

Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment response in gastric cancer: A prospective pilot study.

Skubleny D, Lin A, Garg S, McLean R, McCall M, Ghosh S World J Gastrointest Oncol. 2023; 15(2):303-317.

PMID: 36908322 PMC: 9994053. DOI: 10.4251/wjgo.v15.i2.303.

References

Sharma A . Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity. Nanomedicine (Lond). 2017; 12(17):2137-2148. DOI: 10.2217/nnm-2017-0184. View

Li W, Li C, Zhou T, Liu X, Liu X, Li X . Role of exosomal proteins in cancer diagnosis. Mol Cancer. 2017; 16(1):145. PMC: 5576100. DOI: 10.1186/s12943-017-0706-8. View

Kaparakis M, Walduck A, Price J, Pedersen J, van Rooijen N, Pearse M . Macrophages are mediators of gastritis in acute Helicobacter pylori infection in C57BL/6 mice. Infect Immun. 2008; 76(5):2235-9. PMC: 2346689. DOI: 10.1128/IAI.01481-07. View

Liu X, Zhao P, Wang X, Wang L, Zhu Y, Gao W . Triptolide Induces Glioma Cell Autophagy and Apoptosis via Upregulating the ROS/JNK and Downregulating the Akt/mTOR Signaling Pathways. Front Oncol. 2019; 9:387. PMC: 6528693. DOI: 10.3389/fonc.2019.00387. View

Petersen C, Weis V, Nam K, Sousa J, Fingleton B, Goldenring J . Macrophages promote progression of spasmolytic polypeptide-expressing metaplasia after acute loss of parietal cells. Gastroenterology. 2014; 146(7):1727-38.e8. PMC: 4035414. DOI: 10.1053/j.gastro.2014.02.007. View

Zhang D, Li X, Liu B . Objective characterization of GE discovery CT750 HD scanner: gemstone spectral imaging mode. Med Phys. 2011; 38(3):1178-88. DOI: 10.1118/1.3551999. View

Mitani Y, Oue N, Matsumura S, Yoshida K, Noguchi T, Ito M . Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene. 2007; 26(30):4383-93. DOI: 10.1038/sj.onc.1210215. View

Chen Z, Gao Y, Hou R, Ding D, Song D, Wang D . MicroRNA-206 facilitates gastric cancer cell apoptosis and suppresses cisplatin resistance by targeting MAPK2 signaling pathway. Eur Rev Med Pharmacol Sci. 2019; 23(1):171-180. DOI: 10.26355/eurrev_201901_16761. View

Li S, Li B, Wang J, Zhang D, Liu Z, Zhang Z . Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction. Oncol Res. 2017; 25(1):93-97. PMC: 7840763. DOI: 10.3727/096504016X14719078133564. View

10.

Sun M, Xu B, Wu Q, Chen W, Cai S, Zhang H . Cisplatin-Resistant Gastric Cancer Cells Promote the Chemoresistance of Cisplatin-Sensitive Cells via the Exosomal RPS3-Mediated PI3K-Akt-Cofilin-1 Signaling Axis. Front Cell Dev Biol. 2021; 9:618899. PMC: 7905060. DOI: 10.3389/fcell.2021.618899. View

11.

Lee D, Kim S, Im S, Oh D, Kim T, Han J . Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study. Eur Radiol. 2015; 26(8):2771-8. DOI: 10.1007/s00330-015-4105-5. View

12.

Miller A, Hoogstraten B, STAQUET M, Winkler A . Reporting results of cancer treatment. Cancer. 1981; 47(1):207-14. DOI: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. View

13.

De Cecco C, Darnell A, Rengo M, Muscogiuri G, Bellini D, Ayuso C . Dual-energy CT: oncologic applications. AJR Am J Roentgenol. 2012; 199(5 Suppl):S98-S105. DOI: 10.2214/AJR.12.9207. View

14.

Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J . miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol. 2011; 69(3):723-31. DOI: 10.1007/s00280-011-1752-3. View

15.

Zhang H, Deng T, Liu R, Ning T, Yang H, Liu D . CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020; 19(1):43. PMC: 7045485. DOI: 10.1186/s12943-020-01168-8. View

16.

Butera G, Pacchiana R, Donadelli M . Autocrine mechanisms of cancer chemoresistance. Semin Cell Dev Biol. 2017; 78:3-12. DOI: 10.1016/j.semcdb.2017.07.019. View

17.

An Y, Zhang Z, Shang Y, Jiang X, Dong J, Yu P . miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis. 2015; 6:e1766. PMC: 4669702. DOI: 10.1038/cddis.2015.123. View

18.

Yao L, Itoh S, Furuta I . Thymidine phosphorylase expression in oral squamous cell carcinoma. Oral Oncol. 2002; 38(6):584-90. DOI: 10.1016/s1368-8375(01)00113-0. View

19.

Ott K, Fink U, Becker K, Stahl A, Dittler H, Busch R . Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003; 21(24):4604-10. DOI: 10.1200/JCO.2003.06.574. View

20.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View